Emergency treatment and management of anaphylaxis

被引:3
作者
Brockow, K. [1 ,2 ]
Ring, J.
机构
[1] Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, D-80802 Munich, Germany
[2] Tech Univ Munich, Zentrum Allergie & Umwelt GSF TUM, D-80802 Munich, Germany
来源
HAUTARZT | 2013年 / 64卷 / 02期
关键词
Severity; Therapy; Epinephrine; Anaphylaxis educational program; Immediate allergic reaction; CLINICAL-FEATURES; ALLERGY; RESUSCITATION; IMMUNOTHERAPY; PREVENTION; OMALIZUMAB; GUIDELINES; SEVERITY;
D O I
10.1007/s00105-012-2453-5
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Anaphylaxis, the maximal manifestation of an immediate allergic reaction, is a life-threatening systemic reaction. The immediate therapy is chosen according to the clinical manifestations and new German guidelines are in preparation. Required measures include immediate removal of allergen, adequate positioning, assessment of severity and organ involvement and activation of emergency medical services. In anaphylaxis with primarily cardiovascular involvement, epinephrine is the treatment of choice and given together with volume substitution, oxygen, H-1-antihistamines and corticosteroids. Obstruction of the airways is treated with intramuscular and inhaled epinephrine, or alternatively beta(2)-sympathicomimetics, and oxygen. Abdominal or cutaneous involvement, such as generalized urticaria, usually can be treated with intravenous H-1-antihistamines, glucocorticoids and surveillance. In patients with anaphylaxis, the elicitor of the reaction has to be diagnosed by allergy testing. Patients with sustained risk for anaphylaxis should receive a self-medication kit and should be educated about behavioral patterns needed for prophylaxis and therapy of anaphylactic reactions. Patient educational intervention increases knowledge about anaphylaxis, and practical competence and thus, is a basis of a successful management of anaphylaxis.
引用
收藏
页码:81 / 87
页数:7
相关论文
共 23 条
  • [1] Oral peanut immunotherapy in children with peanut anaphylaxis
    Blumchen, Katharina
    Ulbricht, Helen
    Staden, Ute
    Dobberstein, Kerstin
    Beschorner, John
    de Oliveira, Lucila Camargo Lopes
    Shreffler, Wayne G.
    Sampson, Hugh A.
    Niggemann, Bodo
    Wahn, Ulrich
    Beyer, Kirsten
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 126 (01) : 83 - 91
  • [2] Brockow K, 2006, MMW Fortschr Med, V148, P28
  • [3] Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients
    Brockow, K.
    Jofer, C.
    Behrendt, H.
    Ring, J.
    [J]. ALLERGY, 2008, 63 (02) : 226 - 232
  • [4] Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial
    Brockow, K
    Kiehn, M
    Riethmuller, C
    Vieluf, D
    Berger, J
    Ring, J
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (04) : 458 - 463
  • [5] Brockow K, 2010, ALLERGOLOGIE, V33, P309
  • [6] Brockow K, 2008, ALLERGO J, V17, P556
  • [7] Anaphylaxis to radiographic contrast media
    Brockow, Knut
    Ring, Johannes
    [J]. CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 11 (04) : 326 - 331
  • [8] Clinical features and severity grading of anaphylaxis
    Brown, SGA
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (02) : 371 - 376
  • [9] Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
    Carter, Melody C.
    Robyn, Jamie A.
    Bressler, Peter B.
    Walker, John C.
    Shapiro, Gail G.
    Metcalfe, Dean D.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (06) : 1550 - 1551
  • [10] Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review
    Choo, K. J. L.
    Simons, E.
    Sheikh, A.
    [J]. ALLERGY, 2010, 65 (10) : 1205 - 1211